30 Jul 2008 09:51
The following announcement replaces the "Update on US International OTCQX trading platform" announcement made on 29 July 2008, at 13.47 with number 1289A. The website address for ReGen should have been given as www.regentherapeutics.com/regenplc/investors/adr/ rather than www.regentherapeutics.com/reganplc/investors/adr/. All other information remains the same.
For Immediate Release
30 July 2008
ReGen Therapeutics Plc (AIM: RGT)
Update on US International OTCQX trading platform
ReGen Therapeutics Plc ("ReGen" or the "Company") announced on the 14th July that its American Depository Receipts (ADRs) were trading on the US International OTCQX under the symbol REGUY. ReGen now confirms that it can issue ADRs in respect of up to 25% of its issued share capital. Each ADR represents 20 of ReGen ordinary shares. ReGen retains its primary listing on AIM.
Further details of ReGen's ADR programme can be found at
www.regentherapeutics.com/regenplc/investors/adr/
ENDS
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish
Tel No 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel No 020 7448 9800
Adrian Duffield/Jon Davies
College Hill Associates
Tel No 020 7457 2020
Notes to Editors:
About ReGen Therapeutics
ReGen Therapeutics PLC is a UK-based biopharmaceutical company engaged in the acquisition and development of therapies related to age related disorders including Alzheimer's disease, Parkinson's disease and other degenerative neurological disorders.
The Company is focused particularly on technologies that address large unmet medical need to maintain healthy brain ageing, as well as rehabilitation after traumatic brain injury. ReGen's product pipeline comprises ColostrininTM a nutraceutical that is in full commercial production and had been launched to the professional channel in the USA and Australia under the brand name CogniSureTM; a drug development programme based on ColostrininTM-derived peptides; and Phase II clinical trials on a novel formulation of Zolpidem for the treatment of brain trauma and reversal of dormancy.
About International OTCQX
International OTCQX provides a gateway to U.S. securities markets for international companies that are listed on a qualified non-U.S. exchange and provide ongoing disclosure in English to U.S. investors. More importantly, International OTCQX distinguishes the reputable international issuers from the 8,000 over-the-counter (OTC) securities traded in the U.S. Only leading companies that have substantial operating businesses and provide credible disclosure to the public are eligible for inclusion on the premium-tier International OTCQX, which commenced trading on March 5, 2007. For more about International OTCQX, visit www.otcqx.com.
About Pink OTC Markets Inc.
Pink OTC Markets Inc. provides the leading inter-dealer electronic quotation and trading system in the over-the-counter (OTC) securities market. We create innovative technology and data solutions to efficiently connect market participants, improve price discovery, increase issuer disclosure, and better inform investors. Pink OTC Markets operates the third largest U.S. equity trading venue which includes both the elite OTCQX market tiers for strong OTC-traded companies that can satisfy financial and disclosure listing standards and Pink Sheets for all other OTC quoted securities.
Over 230 financial service firms, including the ten largest U.S. investment banks, actively make markets in OTCQX and Pink Sheets quoted securities and in 2007 these firms traded over $160 billion of OTCQX and Pink Sheets securities. Pink OTC Markets offers widespread access to all U.S. broker-dealers, enabling investors to seamlessly trade these securities through their institutional, online, or full service brokers.
Pink OTC Markets is headquartered in New York City.
To learn more about how Pink OTC Markets' products and services make OTC markets more transparent, informed, and efficient, please visit our websites at www.pinksheets.com and www.otcqx.com or contact us at info@pinkotc.com.'